Volume 30, Number 9—September 2024
CME ACTIVITY - Research
Clinical Aspects and Disease Severity of Streptococcus dysgalactiae Subspecies equisimilis Bacteremia, Finland1
Viivi Nevanlinna
, Janne Aittoniemi, Reetta Huttunen, Tiina Luukkaala, and Sari Rantala
, Janne Aittoniemi, Reetta Huttunen, Tiina Luukkaala, and Sari Rantala
Table 5
Laboratory test results of patients with Streptococcus dysgalactiae subspecies equisimilis bacteremia in relation to nonsevere and severe disease during November 2015–November 2019, Finland*
| Laboratory test | Nonsevere disease, n = 142 | Severe disease, n = 17 | p value |
|---|---|---|---|
| Leukocyte count, × 109 cells/L | |||
| Day 0 | 16 (11–19) | 14 (11–21) | 0.973 |
| Day 1 | 13 (10–18) | 15 (11–23) | 0.370 |
| Day 2 | 11 (8–15) | 15 (10–21) | 0.032 |
| Day 3 | 10 (7–12) | 15 (10–16) | 0.020 |
| Highest† |
17 (12–21) |
19 (12–25) |
0.488 |
| C-reactive protein, mg/L | |||
| Day 0 | 70 (20–179) | 196 (21–344) | 0.093 |
| Day 1 | 177 (123–274) | 195 (94–360) | 0.439 |
| Day 2 | 207 (124–283) | 256 (120–348) | 0.329 |
| Day 3 | 149 (79–217) | 217 (124–305) | 0.030 |
| Day 4 | 99 (51–163) | 193 (100–260) | 0.009 |
| Highest‡ |
237 (163–320) |
328 (162–385) |
0.202 |
| Creatinine, µmol/L | |||
| Day 0 | 94 (78–122) | 113 (84–203) | 0.046 |
| Day 1 | 93 (81–121) | 135 (89–182) | 0.043 |
| Day 2 |
94 (73–121) |
103 (80–175) |
0.137 |
| Platelet count, × 109/L | |||
| Day 0 | 196 (159–234) | 169 (143–216) | 0.178 |
| Day 2 |
183 (146–217) |
142 (105–212) |
0.175 |
| Highest ALT,§ U/L | 26 (18–41) | 58 (25–69) | 0.052 |
*Values are median (interquartile range) except as indicated. Severe disease was defined as treatment in the intensive care unit or death within 30 days after hospital admission. ALT, alanine aminotransferase. †Highest count during days 0–3. ‡Highest level during days 0–4. §Highest level during days 0–4.
1Preliminary results from this study were presented at the European Congress of Clinical Microbiology and Infectious Diseases; April 27–30, 2024; Barcelona, Spain.
Page created: July 02, 2024
Page updated: August 22, 2024
Page reviewed: August 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.